

Ad hoc announcement pursuant to Art. 53 LR

## **Ypsomed completes CHF 50 million share repurchase program**

**Burgdorf, 18 March 2026, 07:00 a.m. – Ypsomed Holding AG (SIX: YPSN) announces the completion of its public share repurchase offer of CHF 50 million. The settlement will take place on 20 March 2026.**

On 2 March 2026, Ypsomed Holding AG announced that it would repurchase its own registered shares with a total value of up to CHF 50 million at a fixed price of CHF 300.00 per registered share as part of a public buyback offer. This corresponds to a maximum of 166,667 registered shares, or 1.22 % of the company's current share capital. The offer period ran from 3 March 2026 to 17 March 2026, 12:00 p.m. CET.

The public buyback offer was part of a broader share buyback program of CHF 150 million, with shares worth CHF 100 million having already been repurchased from the main shareholder, Dr. h.c. Willy Michel. As part of the buyback agreement, Dr. h.c. Willy Michel committed not to tender any registered shares in the public buyback offer.

### **Result of the public buyback offer**

Under the terms of the buyback offer, shareholders tendered a total of 1,088,577 registered shares. As this exceeded the maximum of 166,667, shares will be allocated on a pro rata basis. The exact allocation ratio is 15.31 %. Payment of the net buyback price and delivery of the registered shares will take place on Friday, 20 March 2026. Further information, including the buyback offer document, is available at [www.ypsomed.com/investors](http://www.ypsomed.com/investors).

### **Contact**

Sam Ghezlbash, Head of Investor Relations and M&A, Ypsomed Holding AG  
+41 76 228 51 45, [sam.ghezlbash@ypsomed.com](mailto:sam.ghezlbash@ypsomed.com)

### **Ypsomed Group**

Ypsomed is the leading developer and manufacturer of injection systems for the self-administration of liquid medication. As the reliable partner of pharmaceutical and biotech companies for more than 40 years, Ypsomed provides tailored selfcare solutions to meet specific needs. Backed by a proven track record, Ypsomed offers the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices. Delivered with best-in-class execution and ready to integrate with digital health services, these solutions help simplify therapy and improve the quality of life for millions of people living with chronic conditions. Ypsomed is headquartered in Burgdorf, Switzerland, and operates a global network of manufacturing facilities. More than 2 000 employees worldwide are committed every day to making selfcare simpler and easier.

### **Ypsomed Holding AG**

Brunnmattstrasse 6  
3401 Burgdorf  
Switzerland  
[www.ypsomed.com](http://www.ypsomed.com)